ClinicalTrials.gg
RecruitingNCT06557265Updated Jun 4, 2026

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

A Phase 1/2 interventional study of NKX019 and Fludarabine, Cyclophosphamide in Lupus Nephritis and Primary Membranous Nephropathy, sponsored by Nkarta, Inc.. Recruiting at 19 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Nkarta, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 114 studies in Lupus Nephritis with a site in United States — 39 open to participants now, 51 under way, 5 of them phase 3. Lupus Nephritis · United States.

Planned enrollment
30th of 100
120 · median 50
Started
2024
with 15 others
Phase 1/2
12 of 114
6 open now
Primary completion
2027-04
later than 9 of 49 live
Registered
84th of 114
by date

Among the 114 studies in Lupus Nephritis with a site in United States, this one is the 30th largest by planned enrollment of the 100 interventional ones that give a count, is one of 16 that started in 2024, is one of 12 in phase 1/2, reaches primary completion later than 9 of the 49 other live ones, and was the 84th registered.

Lupus Nephritis

343 studies on the registry are indexed under Lupus Nephritis; 137 are open to participants now.

Browse Lupus Nephritis studies →

Open to participants now

39 of the 114 studies in Lupus Nephritis with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Lupus Nephritis studies recruiting now, 30 (34%) set no upper age limit and 52 (58%) stop at 75 or younger; 30 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Lupus Nephritis with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

Read the detailed description

Dose escalation of NKX019 will utilize a "3+3" design to determine the recommended dose(s) for enrolling additional participants across indications. The study will evaluate safety and tolerability, preliminary efficacy, pharmacokinetics, pharmacodynamics in participants with autoimmune diseases. Participants will receive a cycle consisting of lymphodepletion with fludarabine and cyclophosphamide (Flu/Cy), followed by three doses of NKX019. Participants who are cytopenic may receive a modified LD regimen of Cy alone.

03

Conditions studied

  • Lupus Nephritis
  • Primary Membranous Nephropathy

Browse trials for

Keywords

  • CD19
  • CAR
  • Allogeneic
  • NKX019
  • Interleukin 15
  • Cell Therapy
  • Immunotherapy
  • Adoptive cell therapy
  • Lupus Nephritis
  • Ntrust-1
  • LN
  • Primary Membranous Nephropathy
  • pMN
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria:

  1. Age ≥18 and ≤75
  2. Signed form and ability to adhere to the study visit schedule and comply with other protocol requirements
  3. Women of must have negative pregnancy tests at screening and baseline, and agree to abstinence or acceptable from 2 weeks prior to the first dose through 1 year after the last dose
  4. Progression despite maximal tolerated doses of renin-angiotensin system (RAS) blockade agents
  5. . For participants taking chronic for management of the disease under study, the prednisone (or equivalent) dose must be ≤20 mg/day at 2 weeks prior to Screening and stable for ≥ 14 days before start of Screening
  6. For participants on immunosuppressives or immunomodulators (other than corticosteroids), all doses must be stable for ≥ 4 weeks prior to Screening

LN-specific Inclusion Criteria:

  1. Score of 10 or more points on the American College of Rheumatology (ACR) 2019 classification criteria for SLE
  2. Active proven lupus nephritis Class III or Class IV without Class V overlap using the 2018 International Society of Nephrology and Renal Pathology Society (ISN/RPS) criteria as evidenced on kidney biopsy during consent or within 6 months before screening. The biopsy must have at least mild to moderate activity score and no more than moderate chronicity index per NIH indices
  3. Active renal disease as defined by urinary protein:creatinine ratio (UPCR) ≥ 1.5 g/g or proteinuria ≥1.5 g/day on a 24-hour collection and ≤ 7 g/day by either measure
  4. One or more of the following: positive antinuclear antibodies (ANA) ≥ 1:80 at screening OR positive anti-dsDNA OR positive anti-Smith (anti-Sm)
  5. LN defined as having received ≥ 2 prior therapies for LN ( and corticosteroid/or immunomodulatory agent, and corticosteroid at therapeutic range for at least 90 days), and had an inadequate response to therapy despite being on a therapeutic dose for ≥ 90 days

pMN-specific Inclusion Criteria:

  1. Evidence of pMN by renal biopsy during screening or within 6 months before screening
  2. Active renal disease at screening defined by spot UPCR ≥ 3.5 g/g or proteinuria ≥ 3.5 g/day on a 24-hour collection
  3. Presence of primary membranous nephropathy autoantibodies
  4. Refractory or intolerant to at least 1 induction therapy for pMN (immunosuppressant and corticosteroid or immunomodulatory agent and/corticosteroid) and defined as not achieving a complete remission after 180 days, or partial remission after 90 days

General Exclusion Criteria:

  1. \< 45 ml/min/1.73 m\^2
  2. Currently requiring renal dialysis or expected to require dialysis during the study period
  3. Previous solid organ or hematopoietic cell transplant or planned transplant within study treatment period
  4. Congenital or acquired immunodeficiency resulting in severe infection or those receiving chronic immunoglobulin replacement therapy
  5. Liver disease or dysfunction, including cirrhosis and/or , alanine aminotransferase, or ≥ 3 times the
  6. Pulmonary comorbidity including or asthma requiring daily oral steroids, resting hypoxemia (\<92% oxygen saturation via pulse oximetry) on room air, or significant smoking history (i.e. >10 pack/year) with active pulmonary disease
  7. Bone marrow insufficiency unrelated to active underlying disease with white blood cell count \< 3,000/mm\^3; levels \< 9 gm/dL \< 1500/mm\^3; count \< 100,000/mm\^3
  8. Major cardiac disease, abnormalities, or interventions as defined by, but not limited to:

    1. Uncontrolled angina or unstable life-threatening arrhythmias
    2. History of myocardial infarction within 12 weeks prior to the first dose of NKX019
    3. Any prior coronary artery bypass graft surgery
    4. ≥ Class III (NYHA) congestive heart failure (CHF), significantly decreased (EF ≤ 40%), or severe cardiac insufficiency.
    5. Prolongation of the corrected for heart rate (QTc) (Fridericia) interval of > 480 msec
    6. Peripheral artery bypass graft surgery, pulmonary embolism, or other ≥ Grade 2 thrombotic or embolic events within 12 weeks prior to the first dose of NKX019
    7. Uncontrolled hypertension (systolic BP > 160mmHg and/or diastolic BP > 90mmHg) despite therapy
  9. Active bleeding disorders
  10. Any overlapping autoimmune condition for which the condition or the treatment of the condition may affect the study assessments or outcomes (eg, anti-GBM antibody glomerulonephritis or any condition for additional immunosuppression is indicated); conditions that could cause a secondary nephropathy (eg, infections, liver disease, tumors or drugs); or kidney biopsy-confirmed significant renal disease other than disease under study (eg, diabetic nephropathy, hypertensive nephropathy). Overlapping conditions for which the condition or treatment is not expected to affect assessments or outcomes (eg, Sjögren's syndrome, rheumatoid arthritis) are not excluded
  11. Pregnancy, breast feeding or, if of childbearing potential, not using adequate contraceptive precautions
  12. Current infection requiring active systemic anti-infective therapy or recent acute infection requiring systemic therapy within 30 days of planned LD
  13. History of positive antibody or test positive at screening, or C positive at screening, active tuberculosis (TB) or latent TB requiring suppressive therapy
  14. Major surgery within 28 days prior to the first dose of NKX019 or any surgery from which the participant has not recovered or has ongoing complications
  15. within 5 years of screening, with the exception of basal and squamous cell carcinomas treated by complete excision. Participants with cervical dysplasia that is cervical intraepithelial neoplasia but have been treated with conization or loop electrosurgical excision procedure and have had a normal repeat Papanicolaou test are allowed
  16. Prior cellular therapy including mesenchymal, CAR-T or CAR-NK cells
  17. Central nervous system (CNS) comorbidity or any autoimmune disease with CNS involvement within 90 days prior to the first dose of NKX019 as well as active CNS lupus within 1 year prior to screening
  18. Any other acute or chronic medical or psychiatric condition, or known laboratory abnormality that, in the Investigator's opinion, is expected to interfere or impact study participation
  19. Current participation in another interventional clinical trial

    a. Potential participants can be considered for enrollment after product of 5 half-lives or 30 days, whichever is longer

  20. Currently taking or known need for any of the medications prohibited in the study protocol
  21. Known or to the study treatment including LD; or other components such as human serum albumin or dimethyl sulfoxide

LN-specific Exclusion Criteria:

1. Known clinically active antiphospholipid antibody syndrome (APS); or high-risk profile

Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    NKX019 - CAR NK cell therapy

    Phase 1/2: NKX019 plus fludarabine and cyclophosphamide

    Drug: NKX019 · Drug: Fludarabine, Cyclophosphamide

Interventions

  • DrugNKX019

    NKX019 is an investigational allogeneic CD19-Directed CAR NK

  • DrugFludarabine, Cyclophosphamide

    Drug pages: Fludarabine · Cyclophosphamide

    For Lymphodepletion

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability]

    Incidence of DLTs will be evaluated

    Time frame: The first 28 days after the first NKX019 dose

  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Incidence and severity of treatment-emergent adverse events will be evaluated

    Time frame: From the first administration of NKX019 until the last administration of any study treatment + 30 days

  3. Incidence of clinically significant abnormalities in clinical laboratory assessments [Safety and Tolerability]

    Incidence of clinically significant laboratory abnormalities will be evaluated

    Time frame: From the first NKX019 dose until the last follow up visit

Secondary outcomes

  1. LN only: Number of participants who achieved Primary Efficacy Renal Response (PERR), complete renal response (CRR) and partial renal response (PRR)

    Primary Efficacy Renal Response (PERR), complete renal response (CRR) and partial renal response (PRR) to treatment will be assessed based on European Alliance of Associations for Rheumatology (EULAR)/European Renal Association-European Dialysis and Transplantation Association (ERA-EDTA) criteria

    Time frame: Up to 2 years after NKX019 infusion

  2. LN only: Assessment of Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) remission over time

    Time frame: Up to 2 years from NKX019 infusion

  3. LN only: Change from baseline in Systemic Lupus Erythematosus (SLE) Disease Activity Index 2000 (SLEDAI-2K) score over time

    The SLEDAI-2K score falls between 0 and 105. A higher score represents greater disease activity

    Time frame: Up to 2 years from NKX019 infusion

  4. pMN only: Number of participants who achieved complete remission (CR) and partial remission (PR) and their components (Couser 2017)

    Time frame: Up to 2 years from NKX019 infusion

  5. pMN only: Change from baseline in serum albumin

    Time frame: Up to 2 years after NKX019 infusion

  6. pMN only: % change from baseline in estimated glomerular filtration rate (eGFR)

    Time frame: Up to 2 years after NKX019 infusion

  7. Maximum Concentration (Cmax) of NKX019 in peripheral blood

    Time frame: Up to 2 years after NKX019 infusion

  8. Time to Cmax (Tmax) of NKX019 in peripheral blood

    Time frame: Up to 2 years after NKX019 infusion

  9. Area Under the Concentration-time Curve (AUC) of NKX019 in peripheral blood

    Time frame: Up to 2 years after NKX019 infusion

  10. Half-life (t1/2) of NKX019 in peripheral blood

    Time frame: Up to 2 years after NKX019 infusion

  11. Duration of Persistence of NKX019 in peripheral blood

    Time frame: Up to 2 years after NKX019 infusion

  12. Assess humoral and cellular immunogenicity over time with validated methods that include: a cell-based flow cytometry assay for anti-NKX019 antibodies and an antigen bead-assay using flow cytometry for detection of anti-HLA antibodies

    Time frame: Up to 2 years after NKX019 infusion

  13. Evaluation of the effect of treatment on background therapies

    Proportion of subjects requiring rescue therapy over time

    Time frame: Up to 2 years after NKX019 infusion

  14. Evaluation of the effect of treatment on background therapies

    Proportion of subjects who are steroid free over time

    Time frame: Up to 2 years after NKX019 infusion

  15. Evaluation of the effect of treatment on background therapies

    Cumulative corticosteroid dose over time

    Time frame: Up to 2 years after NKX019 infusion

  16. Evaluation of the effect of treatment on background therapies

    Proportion of subjects receiving ≤5 mg daily prednisone (or equivalent) over time

    Time frame: Up to 2 years after NKX019 infusion

  17. Evaluation of the effect of treatment on background therapies

    Proportion of subjects receiving ≤7.5 mg daily prednisone (or equivalent) over time

    Time frame: Up to 2 years after NKX019 infusion

07

Study locations

18 of 19 sites recruiting
  • Nkarta Investigational Site
    Little Rock, Arkansas 72201, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Tustin, California 92780, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Gainesville, Florida 32601, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Miami, Florida 33133, United States
    Withdrawn

    Not enrolling at this site.

  • Nkarta Investigational Site
    Plantation, Florida 33317, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Tampa, Florida 33602, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Atlanta, Georgia 30303, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Chicago, Illinois 60612, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    New Orleans, Louisiana 70112, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Worcester, Massachusetts 01608, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Summit, New Jersey 07901, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    New York, New York 10007, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Stony Brook, New York 11794, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Syracuse, New York 13202, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Dallas, Texas 75201, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Houston, Texas 77002, United States
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Parkville, Victoria 3050, Australia
    Recruiting
    • Nkarta Central Contact · Contact
  • Nkarta Investigational Site
    Manati, 00674, Puerto Rico
    Recruiting
    • Nkarta Central Contact · Contact
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Apr 2027, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2024
First posted
Aug 16, 2024
StartActual
Jun 13, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06557265
Lead sponsor
Nkarta, Inc.
Responsible party
Sponsor
First posted
Aug 16, 2024
Start date
Jun 13, 2024
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

Nkarta Central Contact
Contact
clinicaltrials@nkartatx.com
Only Use Email
Nkarta Study Director
study director · Nkarta, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belacabnagene franleucel

Start the discussion